• 1.

    Beitelshees AL, et al. Sodium-glucose cotransporter 2 inhibitors: A case study in translational research. Diabetes 2019; 68:11091120. doi: 10.2337/dbi18-0006

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644657. doi: 10.1056/NEJMc1712572

  • 3.

    Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:21172128. doi: 10.1056/NEJMc1600827

  • 4.

    Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347357. doi: 10.1056/NEJMoa1812389

  • 5.

    Lin YH, et al. Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages. Front Endocrinol (Lausanne) 2019; 10:820. doi: 10.3389/fendo.2019.00820

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

  • 7.

    McMurray JV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:19952008. doi: 10.1056/NEJMoa1911303

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Hahn K, et al. Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat Rev Nephrol 2016; 12:711712. doi: 10.1038/nrneph.2016.159

  • 9.

    Nadkarni GN, et al. Acute kidney injury in patients on SGLT2 inhibitors: A propensity-matched analysis. Diabetes Care 2017; 40:14791485. doi: 10.2337/dc17-1011

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Skrtić M, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57:25992602. doi: 10.1007/s00125-014-3396-4

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Lytvyn Y, et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308:F77F83. doi: 10.1152/ajprenal.00555.2014

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Hahn K, et al. Serum uric acid and acute kidney injury: A mini review. J Adv Res 2017; 8:529536. doi: 10.1016/j.jare.2016.09.006

  • 13.

    O’Neill J, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015; 309:F227F234. doi: 10.1152/ajprenal.00689.2014

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 2019; 139:19851987. doi: 10.1161/CIRCULATIONAHA.118.038881

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Cantarelli C, et al. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am J Transplant 2019; 19:24072414. doi: 10.1111/ajt.15369

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Dekkers CCJ, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 2018; 20:19881993. doi: 10.1111/dom.13301

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Neuen BL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7:845854. doi: 10.1016/S2213-8587(19)30256-6

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 2019; 21:19962000. doi: 10.1111/dom.13754

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Menne J, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med 2019; 16:e1002983. doi: 10.1371/journal.pmed.1002983

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Singh P, et al. Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease. Clin Exp Pharmacol Physiol 2013; 40:138147. doi: 10.1111/1440-1681.12036

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017; 13:629646. doi: 10.1038/nrneph.2017.107

  • 22.

    Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 2015; 87:297307. doi: 10.1038/ki.2014.287

  • 23.

    Sayour AA, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 2019; 17:127. doi: 10.1186/s12967-019-1881-8

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Chang YK, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016; 11:e0158810. doi: 10.1371/journal.pone.0158810

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Fujita Y, et al. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: A prospective cohort study. Sci Rep 2019; 9:14871. doi: 10.1038/s41598-019-51207-8

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Chu C, et al. The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press Res 2019; 44:149157. doi: 10.1159/000498963

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Neumiller JJ, Kalyani RR. How does CREDENCE inform best use of SGLT2 inhibitors in CKD? Clin J Am Soc Nephrol 2019; 14:16671669. doi: 10.2215/CJN.05340419

    • Crossref
    • Search Google Scholar
    • Export Citation

SGLT2 Inhibition and Acute Kidney Injury Friend or Foe?

  • 1 George Vasquez Rios, MD, is in the internal medicine department, Saint Louis University School of Medicine, and the division of nephrology, Icahn School of Medicine at Mount Sinai.
Restricted access
Save